179 related articles for article (PubMed ID: 35847040)
1. Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform.
Kabir M; Padilha EC; Shah P; Huang R; Sakamuru S; Gonzalez E; Ye L; Hu X; Henderson MJ; Xia M; Xu X
Front Pharmacol; 2022; 13():899536. PubMed ID: 35847040
[TBL] [Abstract][Full Text] [Related]
2.
Work HM; Kandel SE; Lampe JN
Drug Metab Dispos; 2024 May; ():. PubMed ID: 38702193
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 versus Neonatal Cytochrome P450 3A7.
Godamudunage MP; Grech AM; Scott EE
Drug Metab Dispos; 2018 Sep; 46(9):1329-1337. PubMed ID: 29991575
[TBL] [Abstract][Full Text] [Related]
4. Predictive Models for Human Cytochrome P450 3A7 Selective Inhibitors and Substrates.
Xu T; Kabir M; Sakamuru S; Shah P; Padilha EC; Ngan DK; Xia M; Xu X; Simeonov A; Huang R
J Chem Inf Model; 2023 Feb; 63(3):846-855. PubMed ID: 36719788
[TBL] [Abstract][Full Text] [Related]
5. Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening.
Work HM; Kandel SE; Lampe JN
Sci Rep; 2021 Sep; 11(1):19443. PubMed ID: 34593846
[TBL] [Abstract][Full Text] [Related]
6. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.
Li H; Lampe JN
Arch Biochem Biophys; 2019 Sep; 673():108078. PubMed ID: 31445893
[TBL] [Abstract][Full Text] [Related]
7. Overlapping between CYP3A4 and CYP3A7 expression in the fetal human liver during development.
Fanni D; Fanos V; Ambu R; Lai F; Gerosa C; Pampaloni P; Van Eyken P; Senes G; Castagnola M; Faa G
J Matern Fetal Neonatal Med; 2015 Jul; 28(11):1291-1295. PubMed ID: 25208228
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
9. Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7.
Neunzig I; Drăgan CA; Widjaja M; Schwaninger AE; Peters FT; Maurer HH; Bureik M
Biochim Biophys Acta; 2011 Jan; 1814(1):161-7. PubMed ID: 20637317
[TBL] [Abstract][Full Text] [Related]
10. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
Yamaori S; Yamazaki H; Suzuki A; Yamada A; Tani H; Kamidate T; Fujita Ki; Kamataki T
Biochem Pharmacol; 2003 Dec; 66(12):2333-40. PubMed ID: 14637191
[TBL] [Abstract][Full Text] [Related]
11. HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation.
Work HM; Hackett JC; Lampe JN
Drug Metab Dispos; 2024 May; 52(6):516-525. PubMed ID: 38267095
[TBL] [Abstract][Full Text] [Related]
12. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity.
Hakkola J; Pelkonen O; Pasanen M; Raunio H
Crit Rev Toxicol; 1998 Jan; 28(1):35-72. PubMed ID: 9493761
[TBL] [Abstract][Full Text] [Related]
13. Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors.
Betts S; Björkhem-Bergman L; Rane A; Ekström L
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):261-6. PubMed ID: 25689036
[TBL] [Abstract][Full Text] [Related]
14. Loss of CYP3A7 gene induction by 1,25-dihydroxyvitamin D3 is caused by less binding of VDR to the proximal ER6 in CYP3A7 gene.
Hara H; Yasunami Y; Adachi T
Biochem Biophys Res Commun; 2004 Sep; 321(4):909-15. PubMed ID: 15358113
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis for the Diminished Ligand Binding and Catalytic Ability of Human Fetal-Specific CYP3A7.
Sevrioukova IF
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072457
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
17. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
18. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele.
Sim SC; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Pharmacogenet Genomics; 2005 Sep; 15(9):625-31. PubMed ID: 16041241
[TBL] [Abstract][Full Text] [Related]
19. Human cytochrome P450 3A7 binding four copies of its native substrate dehydroepiandrosterone 3-sulfate.
Liu J; Kandel SE; Lampe JN; Scott EE
J Biol Chem; 2023 Aug; 299(8):104993. PubMed ID: 37392852
[TBL] [Abstract][Full Text] [Related]
20. Identification of CYP3A7 for glyburide metabolism in human fetal livers.
Shuster DL; Risler LJ; Prasad B; Calamia JC; Voellinger JL; Kelly EJ; Unadkat JD; Hebert MF; Shen DD; Thummel KE; Mao Q
Biochem Pharmacol; 2014 Dec; 92(4):690-700. PubMed ID: 25450675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
